Blueprint Neurotherapeutics Network
What is the Neurotherapeutics Grand Challenge?Most nervous system disorders lack effective treatment, and there is no clear solution:
- Basic researchers often lack the resources to develop novel therapeutics strategies to the point where they can attract industry
interest
- Biopharmaceutical companies often hesitate to invest in neurotherapeutics development because there are few clinically validated
targets or strategies, there is a long track record of failure, and many nervous system disorders affect relatively small
populations.
What is the Blueprint Neurotherapeutics Network?The Blueprint established the Neurotherapeutics Network to bridge the gap in drug development between academic and industry
research (View the project pipeline). The Network offers neuroscience researchers a "virtual pharma" to develop promising hit compounds from chemical optimization
through Phase I clinical testing (View the program structure and services offered).
- Successful applicants will receive: funding to conduct biological testing, access to a full range of industry-style drug development
services and expertise, and control of the intellectual property for drug candidates.
- The Network recently announced funding for seven projects focused on drugs for age-related macular degeneration, ALS, Alzheimer's disease, depression, hearing loss, optic neuropathy
and stroke. Please see the complete list of projects, consultants and contractors for more information.
- This NIH webinar describes the Blueprint Neurotherapeutics Network and other efforts to help researchers accelerate drug discovery for neurological
disorders.
(To view or print the PDF or Microsoft Word content on this page, download the free Adobe® Acrobat® Reader® or free Microsoft Word Viewer.)
